Demonstrates 43.2% ORR and 97.3% DCR; PR response rate in 43% of patients
[by Yu, Suin] Abion announced on May 27 that it will present monotherapy data from the global Phase 2 clinical trial of its flagship anticancer drug candidate, ‘vabametkib (ABN401),’ at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. The conference is scheduled to take place in Chicago, USA, from May 30 to June 3 (local time).
바카라사이트 주사위 is a treatment candidate for non-small cell lung cancer (NSCLC) patients harboring mutations in the hepatocyte growth factor receptor (MET). It is currently undergoing Phase 2 clinical trials in the United States, Taiwan, and Korea. In the trials, the 바카라사이트 주사위 monotherapy group demonstrated an objective response rate (ORR) of 43.2% and a disease control rate (DCR) of 97.3%. Notably, 43% of patients exhibited a partial response (PR), underscoring the substantial therapeutic efficacy of 바카라사이트 주사위 as a monotherapy.
바카라사이트 주사위 highlighted that the clinical trial outcomes not only support the potential of vabametkib as a monotherapy but also suggest its applicability as a combination therapy with immune checkpoint inhibitors (ICIs). The company particularly noted the high partial response (PR) rate observed among patients who had previously received first-line treatment with ‘Keytruda (pembrolizumab),’ a PD-1/PD-L1-targeting immune oncology agent. Based on these findings, 바카라사이트 주사위 expressed confidence in the possibility of expanding its market presence, especially among patients receiving combination therapy or those who have discontinued prior treatment regimens.
“We will also present the ‘Trial in Progress’ data for the ongoing combination therapy cohort (Cohort 2) at ASCO,” an 바카라사이트 주사위 official said. “Based on forthcoming data, we will consider additional combination clinical trials with PD-1/PD-L1 series drugs as deemed necessary.”
On the other hand, in April, 바카라사이트 주사위 entered into a letter of intent (LOI) term sheet with a pharmaceutical company based in Russia for the technology transfer of vabametkib, targeting the Russian market and four additional countries in the Commonwealth of Independent States (CIS). The upcoming ASCO presentation is anticipated to serve as a catalyst for 바카라사이트 주사위’s global commercialization efforts, potentially facilitating the execution of a definitive agreement for technology export.